ALLO Stock Forecast & Price Target

Allogene Therapeutics is projected to have a positive outlook due to its strong pipeline of \"off-the-shelf\" T cell candidates for the treatment of cancer and autoimmune diseases, compelling data on MRD clearance, and a clean safety profile with the potential for outpatient treatment. This could lead to increased confidence from physicians and potentially increased CAR-T adoption in the community setting, resulting in a significant increase in the company's stock price in the next 12 months. Additionally, the company's recent public offering of $175 million of common stock has also increased its financial stability.

Allogene Therapeutics is facing a negative outlook due to limited market potential for its "off-the-shelf" T cell product candidates, as evidenced by the low usage and justification of MRD testing in current medical practice. Additionally, the company's financials may be impacted by the need for advanced manufacturing techniques and potential delays in trials, as seen in the late enrollment for the ALPHA3 study. Finally, partnerships with other companies and incorporation of new technologies may not be enough to overcome the fundamental issues with the company's current pipeline and market potential, leading to a bearish outlook for investors.